COMMUNIQUÉS West-GlobeNewswire

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
25/09/2026
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of Action Biomarker Data from First Two Patients in [...]
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
25/09/2026
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis CLIN2 Grant is a highly competitive award from CIRM to [...]
Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference
25/09/2026
Jonathan Rigby and Will Rust, Ph.D., to Discuss Proposed Merger to Form BetaNova Biotherapeutics and Advance a Differentiated Type 1 Diabetes Cell-Replacement Platform TORONTO and GERMANTOWN, Md., Sept. 25, 2026 (GLOBE [...]
Omotesando Helene Clinic and Maison Privé Clinic Sign Cooperation Agreement on International Medical Exchange and Patient Support
25/09/2026
Aiming to improve information sharing among medical staff and strengthen support systems for patients visiting from abroad TOKYO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Omotesando Helene Clinic (Japan) and Maison Privé [...]
European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease
25/09/2026
Approval is based on NEXUS data and follows positive CHMP opinion in July; first European launch is expected by end of 2026 BARCELONA, Spain and DÜSSELDORF, Germany, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Neuraxpharm Group [...]
Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer
25/09/2026
LONDON and PHILADELPHIA, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, the "Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, today announces the [...]
CROSSJECT strengthens its governance for the industrial and commercial deployment phase
25/09/2026
The Executive Board is expanded to five members: Olivier Lacombe, Didier Morin and Lionel Seltz join Patrick Alexandre and Isabelle Liebschutz A leadership team covering the entire value chain: pharmaceutical [...]
CROSSJECT structure sa gouvernance pour la phase de déploiement industriel et commercial
25/09/2026
Le Directoire est élargi à cinq membres : Olivier LACOMBE, Didier MORIN et Lionel SELTZ rejoignent Patrick ALEXANDRE et Isabelle LIEBSCHUTZ Une direction qui couvre l’intégralité de la chaîne de valeur : développement [...]
CROSSJECT Reports Its First-Half 2026 Results and Presents a Significantly Strengthened Financial Structure
25/09/2026
Cash and cash equivalents of €12.3 million as of June 30, 2026, a 2.4-fold increase compared to December 31, 2025 (€5.1 million), following the €15 million capital increase completed in May. Shareholders’ equity [...]
CROSSJECT publie ses résultats du premier semestre 2026 et présente une structure financière profondément renforcée
25/09/2026
CROSSJECT publie ses résultats du premier semestre 2026 et présente une structure financière profondément renforcée Trésorerie de 12,3 M€ au 30 juin 2026, multipliée par 2,4 par rapport au 31 décembre 2025 (5,1 M€), [...]
IBA to coordinate LIFEDESTINY, a new European LIFE project to advance sustainable PFAS remediation
25/09/2026
Louvain-la-Neuve, Belgium, 25 September 2026, 7 a.m. CEST – IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, today announces it will coordinate the LIFEDESTINY, a new [...]
IBA va coordonner LIFEDESTINY, un nouveau projet européen pour l'élimination durable des PFAS
25/09/2026
Louvain ‑ la ‑ Neuve, Belgique, le 25 septembre 2026, 7h00 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélérateurs de particules, annonce ce jour qu'elle coordonnera LIFEDESTINY [...]
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
25/09/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric [...]
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
25/09/2026
SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized [...]
Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
25/09/2026
Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab FREMONT, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq [...]
UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D. to Its Board of Directors
24/09/2026
WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli [...]
Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D. to Its Board of Directors
24/09/2026
WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli [...]
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
24/09/2026
Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non [...]
NANOBIOTIX fait le point sur ses activités et ses résultats financiers du premier semestre 2026
24/09/2026
Résultats préliminaires prometteurs issus de l’analyse complète des cohortes dans les parties escalade et expansion de dose d’une étude achevée de phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints d’un [...]

Pages